Breakthrough CooperVision MiSight® 1 Day Contact Lens for Childhood Myopia Coming to the United States

This 2019 study evaluated 3-year MiSight efficacy in a randomised clinical trial conducted across four different sites, in Singapore, Canada, Portugal and the UK to yield promising findings, with efficacy results comparable to previous studies, and overall high satisfaction reported by subjects. Eye Care Practitioners can utilise these results to confidently educate patients and their families on the efficacy of this treatment option. The post MiSight 3-Year Data Analysis appeared first on Myopia Profile.

The authors conducted a 2-year double blinded, randomised control trial to evaluate the efficacy of novel contact lens designs for myopia control. Lens I and II induced myopic defocus across a large portion of the retina, while Lens III and IV featured an extended depth of focus incorporating higher order aberrations to modulate retinal image quality. This technology is utilised in the Mark’Ennovy Mylo the and Seed 1-Day Pure EDOF lens. The post Novel Contact Lens Design for Myopia Control appeared first on Myopia Profile.